Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression

Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression

Antibody-dependent cellular phagocytosis (ADCP) by monocytes and macrophages contributes significantly to the efficacy of many therapeutic monoclonal antibodies (mAbs), including anti-CD20 rituximab (RTX) targeting CD20+ B-cell non-Hodgkin lymphomas (NHL). However, ADCP is constrained by various imm...

Full description

Saved in:
Bibliographic Details
Main Authors: Oanh T. P. Nguyen, Sandra Lara, Giovanni Ferro, Matthias Peipp, Sandra Kleinau
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
anti-CD20 antibody
apoptosis
CD47
cancer immunotherapy
monocyte
phagocytosis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1483617/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items